Examining the profile of high-potency cannabis and its association with severity of cannabis dependence
- PMID: 26213314
- PMCID: PMC4611354
- DOI: 10.1017/S0033291715001178
Examining the profile of high-potency cannabis and its association with severity of cannabis dependence
Abstract
Background: Cannabis use is decreasing in England and Wales, while demand for cannabis treatment in addiction services continues to rise. This could be partly due to an increased availability of high-potency cannabis.
Method: Adults residing in the UK were questioned about their drug use, including three types of cannabis (high potency: skunk; low potency: other grass, resin). Cannabis types were profiled and examined for possible associations between frequency of use and (i) cannabis dependence, (ii) cannabis-related concerns.
Results: Frequent use of high-potency cannabis predicted a greater severity of dependence [days of skunk use per month: b = 0.254, 95% confidence interval (CI) 0.161-0.357, p < 0.001] and this effect became stronger as age decreased (b = -0.006, 95% CI -0.010 to -0.002, p = 0.004). By contrast, use of low-potency cannabis was not associated with dependence (days of other grass use per month: b = 0.020, 95% CI -0.029 to 0.070, p = 0.436; days of resin use per month: b = 0.025, 95% CI -0.019 to 0.067, p = 0.245). Frequency of cannabis use (all types) did not predict severity of cannabis-related concerns. High-potency cannabis was clearly distinct from low-potency varieties by its marked effects on memory and paranoia. It also produced the best high, was preferred, and most available.
Conclusions: High-potency cannabis use is associated with an increased severity of dependence, especially in young people. Its profile is strongly defined by negative effects (memory, paranoia), but also positive characteristics (best high, preferred type), which may be important when considering clinical or public health interventions focusing on cannabis potency.
Keywords: Addiction; cannabidiol; cannabis; delta-9-tetrahydrocannabinol; dependence; marijuana.
Figures
![Fig. 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4611354/bin/S0033291715001178_fig1.gif)
![Fig. 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4611354/bin/S0033291715001178_fig2.gif)
Similar articles
-
Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.Addiction. 2014 Jul;109(7):1101-9. doi: 10.1111/add.12508. Epub 2014 Mar 17. Addiction. 2014. PMID: 24628797
-
Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?Addiction. 2014 Oct;109(10):1686-94. doi: 10.1111/add.12634. Epub 2014 Jul 16. Addiction. 2014. PMID: 24894801
-
Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence.JAMA Psychiatry. 2020 Oct 1;77(10):1044-1051. doi: 10.1001/jamapsychiatry.2020.1035. JAMA Psychiatry. 2020. PMID: 32459328 Free PMC article.
-
Psychosocial interventions for cannabis use disorder.Cochrane Database Syst Rev. 2016 May 5;2016(5):CD005336. doi: 10.1002/14651858.CD005336.pub4. Cochrane Database Syst Rev. 2016. PMID: 27149547 Free PMC article. Review.
-
Adverse effects of cannabis.Prescrire Int. 2011 Jan;20(112):18-23. Prescrire Int. 2011. PMID: 21462790 Review.
Cited by
-
Applying machine learning to international drug monitoring: classifying cannabis resin collected in Europe using cannabinoid concentrations.Eur Arch Psychiatry Clin Neurosci. 2024 May 21. doi: 10.1007/s00406-024-01816-w. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 38771330
-
Persistent increased severity of cannabis use disorder symptoms in adolescents compared to adults: a one-year longitudinal study.Eur Arch Psychiatry Clin Neurosci. 2024 May 6. doi: 10.1007/s00406-024-01806-y. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 38709252
-
"Everything is kind of the same except my mind is with me": exploring cannabis substitution in a sample of adults in early recovery from an opioid or stimulant addiction.Harm Reduct J. 2024 Apr 20;21(1):83. doi: 10.1186/s12954-024-01002-0. Harm Reduct J. 2024. PMID: 38643152 Free PMC article.
-
A Burning Problem: Cannabis Lessons Learned from Colorado.Addict Res Theory. 2018;26(1):3-10. doi: 10.1080/16066359.2017.1315410. Epub 2017 Apr 13. Addict Res Theory. 2018. PMID: 38464667 Free PMC article.
-
A systematic review of cannabis health warning research.Prev Med Rep. 2023 Dec 23;37:102573. doi: 10.1016/j.pmedr.2023.102573. eCollection 2024 Jan. Prev Med Rep. 2023. PMID: 38222305 Free PMC article. Review.
References
-
- Coombes R (2014). Cannabis regulation: high time for change? British Medical Journal 348, g3382. - PubMed
-
- Crippa J, Hallak J, Machado-de-Sousa J, Queiroz R, Bergamaschi M, Chagas M, Zuardi A (2012). Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. Journal of Clinical Pharmacy and Therapeutics. - PubMed
-
- Curran VH, Brignell C, Fletcher S, Middleton P, Henry J (2002). Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 164, 61–70. - PubMed
-
- Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, Bianconi F, Gardner-Sood P, O'Connor J, Russo M (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2, 233–238. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical